Literature DB >> 22311262

Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified.

Shuling Wang1, Weidong Li, Ning Liu, Tongxian Zhang, Han Liu, Junjun Liu, Fen Liu, Wei Zhang, Estifanos P Gebreamlak, Yun Niu.   

Abstract

The aim of this study was to investigate the clinicopathologic characteristics and prognosis value for molecular subtypes of low-grade breast carcinoma (LGBC) compared with grade one invasive ductal carcinoma-not otherwise specified (G1-IDC-NOS). A retrospective review of 688 LGBC and 1 037 G1-IDC-NOS patients was classified into four different molecular subtypes based on the IHC-based definitions for ER, PR, and c-erbB-2. In LGBC, lymph node metastasis, the percentage of III/IV TNM stages, the expression of Ki-67 and p53 in luminal A subtype were lower than in other subtypes (P<0.01). In addition, the variations of Ki-67 and p53 expression were observed in different subtypes of G1-IDC-NOS (P<0.01). Compared with G1-IDC-NOS, LGBC has higher proportion in the ER positive, PR positive, HER-2 negative, luminal A subtype, Ki-67 negative, and lymph nodes negative group (P<0.01). Furthermore, the overall survival of luminal A and luminal B is higher than triple-negative and HER-2/neu subtype both in LGBC and G1-IDC-NOS in 262 LGBC and 330 G1-IDC-NOS patients with proper follow-up. The classification of molecular subtype together with clinicopathologic factors can significantly improve the traditional prognosticators in predicting outcome for LGBC and G1-IDC-NOS. And it may contribute to guide the treatment for LGBC and G1-IDC-NOS in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311262     DOI: 10.1007/s12032-012-0174-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  Prognostic relevance of basal cytokeratin expression in operable breast cancer.

Authors:  Piotr Potemski; Renata Kusinska; Cezary Watala; Elzbieta Pluciennik; Andrzej K Bednarek; Radzislaw Kordek
Journal:  Oncology       Date:  2006-01-12       Impact factor: 2.935

2.  The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study.

Authors:  Nicole N Esposito; Mamatha Chivukula; David J Dabbs
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

5.  Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

Authors:  M Colleoni; G Viale; D Zahrieh; L Bottiglieri; R D Gelber; P Veronesi; A Balduzzi; R Torrisi; A Luini; M Intra; S Dellapasqua; A Cardillo; R Ghisini; G Peruzzotti; A Goldhirsch
Journal:  Ann Oncol       Date:  2007-11-06       Impact factor: 32.976

6.  Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.

Authors:  Foluso O Ademuyiwa; Mangesh A Thorat; Rohit K Jain; Harikrishna Nakshatri; Sunil Badve
Journal:  Mod Pathol       Date:  2009-11-27       Impact factor: 7.842

7.  Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Authors:  Alfonso Sánchez-Muñoz; Ana María García-Tapiador; Esther Martínez-Ortega; Rosario Dueñas-García; Ana Jaén-Morago; Ana Laura Ortega-Granados; Mónica Fernández-Navarro; Capilla de la Torre-Cabrera; Basilio Dueñas; Ana Isabel Rueda; Francisco Morales; César Ramírez-Torosa; María Dolores Martín-Salvago; Pedro Sánchez-Rovira
Journal:  Clin Transl Oncol       Date:  2008-10       Impact factor: 3.405

8.  Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Authors:  Magali Lacroix-Triki; Paula H Suarez; Alan MacKay; Maryou B Lambros; Rachael Natrajan; Kay Savage; Felipe C Geyer; Britta Weigelt; Alan Ashworth; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

9.  Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas.

Authors:  Maria A Lopez-Garcia; Felipe C Geyer; Rachael Natrajan; Bas Kreike; Alan Mackay; Anita Grigoriadis; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

10.  Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.

Authors:  Tarek M A Abdel-Fatah; Desmond G Powe; Zsolt Hodi; Jorge S Reis-Filho; Andrew H S Lee; Ian O Ellis
Journal:  Am J Surg Pathol       Date:  2008-04       Impact factor: 6.394

View more
  1 in total

1.  Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.

Authors:  Honghong Shen; Lin Zhao; Li Wang; Xiaozhen Liu; Xia Liu; Junjun Liu; Fengting Niu; Shuhua Lv; Yun Niu
Journal:  Tumour Biol       Date:  2015-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.